Stock Events

Synairgen 

GBX3.92
16
+GBX0.37+10.42% Friday 15:29

Statistics

Day High
4.08
Day Low
3.43
52W High
-
52W Low
-
Volume
100,138
Avg. Volume
-
Mkt Cap
8.1M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

28JunExpected
Q2 2021
Q1 2022
Q2 2022
Q1 2023
Q2 2023
Q1 2024
Q1 2024
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SNG.LSE. It's not an investment recommendation.
Alphabet
72554
GOOGL
Apple
63389
AAPL
Microsoft
59081
MSFT
Amazon
54705
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap127.99B
Vertex Pharmaceuticals is involved in the development of respiratory treatments, including cystic fibrosis therapies, which could compete with Synairgen's respiratory disease treatments.
Gilead Sciences
GILD
Mkt Cap98.35B
Gilead Sciences has a broad portfolio of treatments for viral and respiratory diseases, potentially competing with Synairgen's COVID-19 and other respiratory disease treatments.
Astrazeneca
AZN
Mkt Cap271.67B
AstraZeneca has a strong focus on respiratory and immunology, including treatments for asthma and COPD, which could compete with Synairgen's respiratory therapies.
Galapagos NV
GLPG
Mkt Cap1.97B
Galapagos NV focuses on developing drugs for respiratory diseases, including idiopathic pulmonary fibrosis, directly competing with Synairgen's focus area.
Regeneron Pharmaceuticals
REGN
Mkt Cap130.59B
Regeneron Pharmaceuticals is involved in the development of treatments for respiratory syncytial virus (RSV) and other lung diseases, competing with Synairgen's respiratory focus.
Merck
MRK
Mkt Cap300.25B
Merck & Co. has a diverse drug portfolio that includes treatments for infectious diseases, potentially competing with Synairgen's development of treatments for viral-induced respiratory diseases.
Pfizer
PFE
Mkt Cap164.39B
Pfizer has a broad range of treatments for infectious and respiratory diseases, including COVID-19 vaccines and treatments, competing with Synairgen's respiratory disease focus.
Biogen
BIIB
Mkt Cap29.83B
Biogen focuses on advanced therapies for serious diseases, including potential treatments for lung diseases, which could compete with Synairgen's respiratory disease treatments.
Novartis
NVS
Mkt Cap244.75B
Novartis has a strong presence in the respiratory market, including treatments for asthma and COPD, competing with Synairgen's focus on respiratory diseases.
Sanofi
SNY
Mkt Cap141.43B
Sanofi is involved in the development of treatments for respiratory conditions and infectious diseases, potentially competing with Synairgen's focus on respiratory diseases.

About

Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein that helps regulate the immune system to fight viruses, including coronaviruses. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
Show more...
CEO
Mr. Richard Marsden
Employees
36
Country
GB
ISIN
GB00B0381Z20

Listings

LSE
GB
SNG.LSE
US
SYGGF
F
DE
OMY.F